BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Expectations Audits

JPMorgan at Its Own Ceiling: What a Record Quarter Tells Us About the Price Tag

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
July 29, 2026
in Expectations Audits
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

The filing arrived on July 14, 2026. Buried inside JPMorgan’s Q2 2026 earnings release was a sentence that stopped us: net income of $21.2 billion for a single quarter, more than the entire firm earned in all of 2020. That one comparison tells you how far JPMorgan has traveled since the pandemic froze credit markets and forced the bank to set aside billions for loans it feared would go bad. Today the provisions are modest, the trading floors are humming, and CEO Jamie Dimon is warning that conditions may be “getting close to as good as it gets.” That warning is the story.

In one breath

JPMorgan’s filed numbers show a bank operating near the peak of its own recorded profitability. The stock is priced at its highest earnings multiple in a decade, meaning the market is paying a premium on top of a peak. The open question is whether the quarter that just closed is a new floor or a high-water mark, and the filed history offers reasons to think carefully about which one it is.

How the bank got here

JPMorgan’s reputation for durability was forged in crisis. When Bear Stearns collapsed in March 2008, JPMorgan absorbed it at a price that looked reckless to outsiders and shrewd in hindsight. The bank’s own net income fell 55% in Q2 2008 from the year before, according to that quarter’s earnings release, but it stayed profitable while rivals failed entirely. The phrase “fortress balance sheet” entered the financial vocabulary there, and it stuck because the math backed it up.

Interactive: hover for values. Official data via SEC EDGAR.

The pandemic tested the fortress again. Net interest margin, the spread a bank earns between what it charges borrowers and what it pays depositors, compressed sharply as the Federal Reserve cut rates to near zero. JPMorgan’s net yield on interest-earning assets fell to 2.02% in mid-2020. Revenue growth stalled, and the bank’s earnings multiple was cut roughly in half relative to the broader market. Investors were pricing in a long, low-rate slog.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: JPMorgan and 500+ other names, on the same official data.See the evidence engine →

What followed was the opposite. Rates rose faster than almost anyone expected. By the fiscal year 2025 10-K, JPMorgan was reporting annual revenue of $182.4 billion, up from $119.5 billion in 2020. That is not organic growth alone; it is a bank whose core lending business became dramatically more profitable as the rate environment shifted in its favor.

The quarter the filing describes

Q2 2026 was, by the filed numbers, exceptional in almost every dimension. Net interest income, the bread-and-butter lending spread, came in at $25.6 billion for the quarter. The return on tangible common equity, a measure of how efficiently the bank converts its equity base into profit (think of it as the yield a factory earns on its own machinery), reached 29%. Strip out one-time gains from Visa shares and equity investment sales, and the underlying figure was 23%, still among the highest in the bank’s modern history.

The trading and investment banking businesses added fuel. Markets revenue hit $12.1 billion, up 35% from the same quarter a year earlier, with equity trading nearly doubling year-over-year. Investment banking fees rose 30%. Compared with peers, JPMorgan’s Q2 revenue grew roughly 30% year-over-year, outpacing Bank of America’s 17% and Citigroup’s 15.5%, according to Stockal’s earnings summary. For a bank this size, that gap is wide.

The provision for credit losses, the money set aside for loans that might go bad, was $2.5 billion. That is a relatively contained number given the loan book’s scale, and it signals that the bank currently sees limited stress in its borrower base. Whether that reading holds depends heavily on what the economy does next.

The rate floor underneath it all

Much of JPMorgan’s recent profitability rests on a specific interest-rate environment. The Federal Reserve has held its benchmark rate in a range of 3.50% to 3.75% since the start of 2026, with the effective rate sitting at 3.63% as of July 20, according to the FOMC meeting schedule tracker. That level is high enough to keep lending spreads wide. The bank’s own updated full-year 2026 guidance, issued July 14, projects total net interest income of roughly $105.5 billion for the year, a figure that assumes rates stay roughly where they are.

BullScope TerminalYou just read JPMorgan’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Fed Chair Kevin Warsh has moved away from explicit forward guidance, according to JPMorgan’s own investor insights page, emphasizing that inflation remains above the 2% target after five years. That ambiguity cuts both ways: rates could stay elevated longer, supporting NII, or a slowdown could force cuts that compress the spread again, as happened in 2020. The bank’s guidance is explicitly described as “market dependent.”

At the same time, JPMorgan raised its full-year expense guidance by $2.5 billion, bringing projected total expenses to $107.5 billion, according to MarketScreener’s coverage of the July 14 presentation. Revenue is growing, but so is the cost base, and that compression in the gap between them is worth watching.

What the price tag assumes

Here is where the math and the mood diverge. “The math” is what the filed record justifies on its own terms. “The mood” is what the market is currently willing to pay on top of that record.

Our data show JPMorgan’s trailing price-to-earnings multiple at 16.0 times, against a decade median of 12.1 times. That puts the current multiple at the 100th percentile of its own ten-year range, meaning the stock has never, in the past decade, been priced this richly relative to its own earnings. The price-to-sales multiple tells the same story: 5.0 times against a decade median of 3.5 times, again at the top of its own history.

The forward picture, using GuruFocus’s forward P/E data, puts the multiple at roughly 13.6 times the consensus 2026 EPS estimate of $22.70, per TickerNerd’s analyst aggregation. That is more moderate, but it still assumes earnings continue rising from a quarter that Dimon himself described as near-peak conditions.

The filed revenue growth record is instructive. From 2020 through 2023, JPMorgan’s annual revenue growth averaged roughly 10% a year, driven heavily by the rate cycle. In fiscal year 2025, that growth rate slowed to 2.8%, barely above inflation. The mood embedded in the current multiple requires the growth story to continue. The math from the most recent full year suggests it may already be decelerating.

Reading the numbers

  • $21.2 billion Q2 2026 net income. What it is: profit after all costs and taxes for one quarter. What it means here: this single quarter exceeds JPMorgan’s entire annual net income in 2020, which was roughly $29 billion spread over four quarters. In everyday terms, it is as if a business that used to earn $7,000 a month is now earning $21,000 in a single month. Filed source: Q2 2026 earnings release.
  • 29% ROTCE (23% adjusted). What it is: return on tangible common equity, a measure of profit generated per dollar of the bank’s own capital base. What it means here: for every $100 of equity the bank holds, it earned $23 in the quarter on an adjusted basis. A household analogy: a rental property earning $23,000 a year on a $100,000 investment. The 29% headline includes one-time gains; the 23% adjusted figure is the cleaner read of ongoing operations.
  • P/E at 100th percentile of own decade. What it is: the current earnings multiple ranks higher than every prior observation in ten years of our data. What it means here: a saver buying JPMorgan today is paying more per dollar of profit than at any point in the past decade, including periods when the bank’s growth was faster. Think of it as paying the highest price ever asked for a house on a street where prices are already high.
  • Revenue growth of 2.8% in FY2025. What it is: the year-over-year change in total revenue filed in the 2025 10-K. What it means here: after several years of double-digit expansion, the top line grew about as fast as general inflation. A business growing at 2.8% a year doubles its revenue in roughly 25 years. The current multiple implies investors expect something faster than that.

Sources

  • JPMorgan Q2 2026 earnings release
  • JPMorgan 10-K, fiscal year ended December 31, 2025
  • JPMorgan Q2 2008 earnings release
  • MarketScreener: JPMorgan full-year 2026 guidance
  • FOMC meeting schedule and rate tracker
  • JPMorgan investor insights: Kevin Warsh and July 2026 Fed meeting
  • GuruFocus: JPM forward P/E
  • TickerNerd: JPM analyst EPS estimates
  • Stockal: JPMorgan Q2 2026 earnings summary
  • JPMorgan Q2 2025 earnings release
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read JPMorgan’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Amgen: The Stock Is Priced for a Future the Filings Haven’t Promised Yet

by Moe Alsumidaie, MBA, MSF
September 8, 2026
0

For most of the past decade, Amgen was a reliable but slow-moving machine: a biotech giant that grew revenues at roughly the pace of the broader economy, collected...

Read moreDetails

A 95% Gross Margin and a P/S Below Its Own Median: PTC Therapeutics’ Profitability Flip Is Real, and the Valuation Gap Raises Questions

by Moe Alsumidaie, MBA, MSF
September 4, 2026
0

In one breath PTC Therapeutics spent the better part of a decade burning cash on a pipeline that mostly disappointed. Then, in the twelve months through the fiscal...

Read moreDetails

Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

Before anything else Moderna's filed revenue has fallen every year since 2022, and the company is burning through roughly $600 million a quarter. The stock, at $150.81, prices...

Read moreDetails

United Therapeutics: The Stock Is Priced for Stagnation. The Filings Tell a Different Story.

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Two facts about United Therapeutics sit side by side right now and refuse to make peace. The company has grown earnings per share from $11.54 in 2020 to...

Read moreDetails

Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet

by Moe Alsumidaie, MBA, MSF
September 1, 2026
0

Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug that Medicare ultimately refused to cover. Today the stock sits near $218,...

Read moreDetails
Next Post

The Headline Said "Cooling." The Data Said "Complicated."

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Organon: The Company Earning More Per Sale Than Its Stock Suggests, With a Cloud Still Overhead

September 2, 2026

NVIDIA Secures 4.25 IT-GW Ohio Data Center Capacity and Invests $1.5B in SB Energy to Lock in AI Infrastructure

August 19, 2026

Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet

September 1, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.